Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAM | O43451 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | SI | P14410 | 1/20 | 0.42 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 4/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28055530 | 0.91 | MGAM (0.39) | MGAMGAASIMGAM2TSHR | |
| SCHEMBL1015355 | 0.91 | KMT2A (0.42) | MGAMGAASIMGAM2TSHR | |
| SCHEMBL909706 | 0.90 | EPHX1 (0.46) | MGAMGAASIMGAM2TSHR | |
| SCHEMBL26647720 | 0.83 | BRD4 (0.50) | MGAMGAASIMGAM2TSHR | |
| SCHEMBL2036054 | 0.83 | — | — | |
| SCHEMBL24197361 | 0.83 | BRD4 (0.50) | MGAMGAASIMGAM2TSHR | |
| SCHEMBL12561079 | 0.83 | SCN9A (0.34) | MGAMGAASIMGAM2TSHR | |
| SCHEMBL2906560 | 0.82 | BRD4 (0.35) | BRD4EPHX2SMN1; SMN2EPHX1KMT2A | |
| Ammonia Solution, Strong SCHEMBL27687914 | 0.81 | — | — | |
| SCHEMBL1015154 | 0.81 | GAA (0.54) | MGAMGAASIMGAM2HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4695242-A1 | NOVEL SUBSTITUTED PYRROLE COMPOUNDS, COMPOSITIONS COMPRISING THE SUBSTITUTED PYRROLE COMPOUND, AND METHODS OF USE THEREOF | Meta Pharmaceuticals (HK) Limited (HK) | 2026-02-18 | — | — | EP | disclosed |
| WO-2024212024-A1 | NOVEL SUBSTITUTED PYRROLE COMPOUNDS, COMPOSITIONS COMPRISING THE SUBSTITUTED PYRROLE COMPOUND, AND METHODS OF USE THEREOF | META PHARMACEUTICALS (HK) LIMITED (CN) | 2024-10-17 | — | — | WO | disclosed |
| WO-2024212907-A1 | NOVEL SUBSTITUTED PYRROLE COMPOUNDS, COMPOSITIONS COMPRISING THE SUBSTITUTED PYRROLE COMPOUND, AND METHODS OF USE THEREOF | META PHARMACEUTICALS (HK) LIMITED (CN) | 2024-10-17 | — | — | WO | disclosed |
| US-11530198-B2 | Compositions and methods for treating infections | Vyera Pharmaceuticals, LLC (US) | 2022-12-20 | — | — | US | disclosed |
| US-20200407345-A1 | COMPOSITIONS AND METHODS FOR TREATING INFECTIONS | TURING PHARMACEUTICALS LLC | 2020-12-31 | — | — | US | disclosed |
| US-10774073-B2 | Compositions and methods for treating infections | Vyera Pharmaceuticals, LLC (US) | 2020-09-15 | — | — | US | disclosed |
| US-20200270233-A1 | DHFR INHIBITORS, COMPOSITIONS, AND METHODS RELATED THERETO | Vyera Pharmaceuticals, LLC | 2020-08-27 | — | — | US | disclosed |
| EP-3665165-A1 | DHFR INHIBITORS, COMPOSITIONS, AND METHODS RELATED THERETO | Vyera Pharmaceuticals, LLC (US) | 2020-06-17 | — | — | EP | disclosed |
| CN-111225908-A | DHFR inhibitors, compositions, and methods related thereto | 维耶拉制药有限责任公司 | 2020-06-02 | — | — | CN | disclosed |
| WO-2020054670-A1 | NOVEL HETEROAROMATIC AMIDE DERIVATIVE AND MEDICINE CONTAINING SAME | 科研製薬株式会社 | 2020-03-19 | — | — | WO | disclosed |
| WO-2019032458-A1 | DHFR INHIBITORS, COMPOSITIONS, AND METHODS RELATED THERETO | Vyera Pharmaceuticals, LLC (US) | 2019-02-14 | — | — | WO | disclosed |
| CN-109071486-A | Compositions and methods for treating infections | 维耶拉制药有限责任公司 | 2018-12-21 | — | — | CN | disclosed |
| EP-3411367-A1 | COMPOSITIONS AND METHODS FOR TREATING INFECTIONS | Vyera Pharmaceuticals, LLC (US) | 2018-12-12 | — | — | EP | disclosed |
| WO-2017136556-A1 | COMPOSITIONS AND METHODS FOR TREATING INFECTIONS | TURING PHARMACEUTICALS LLC (US) | 2017-08-10 | — | — | WO | disclosed |
| CN-101636398-A | Pyridopyrimidinone compounds useful in treating sodium channel-mediated diseases or conditions | XENON PHARMACEUTICALS INC | 2010-01-27 | — | — | CN | disclosed |
| EP-2079737-A1 | PYRIDOPYRIMIDINONE COMPOUNDS USEFUL IN TREATING SODIUM CHANNEL-MEDIATED DISEASES OR CONDITIONS | XENON PHARMACEUTICALS INC. (CA) | 2009-07-22 | — | — | EP | disclosed |
| US-20080194616-A1 | PYRIDOPYRIMIDINONE COMPOUNDS USEFUL IN TREATING SODIUM CHANNEL-MEDIATED DISEASES OR CONDITIONS | XENON PHARMACEUTICALS INC. (CA) | 2008-08-14 | — | — | US | disclosed |
| WO-2008097991-A1 | PYRIDOPYRIMIDINONE COMPOUNDS USEFUL IN TREATING SODIUM CHANNEL-MEDIATED DISEASES OR CONDITIONS | XENON PHARMACEUTICALS INC. (CA) | 2008-08-14 | — | — | WO | disclosed |
| US-6395766-B1 | COGNITION ACTIVATORS | MERCK SHARP & DOHME LIMITED (GB) | 2002-05-28 | — | — | US | disclosed |
| WO-1999062899-A1 | TETRAHYDROINDOLONE DERIVATIVES AS GABAAALPHA5 LIGANDS FOR ENHANCING COGNITION | MERCK SHARP & DOHME LIMITED (GB) | 1999-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194616-A1 | PYRIDOPYRIMIDINONE COMPOUNDS USEFUL IN TREATING SODIUM CHANNEL-MEDIATED DISEASES OR CONDITIONS | SCN1A, SCN3A, SCN1B | MGAM 4126/4885GAA 2931/4885SI 2209/4885 |
| US-20200407345-A1 | COMPOSITIONS AND METHODS FOR TREATING INFECTIONS | DHFR, DHODH, QDPR | MGAM 1905/4885GAA 641/4885SI 1423/4885 |
| US-11530198-B2 | Compositions and methods for treating infections | DHFR, DHODH, QDPR | MGAM 1905/4885GAA 641/4885SI 1423/4885 |
| US-20200270233-A1 | DHFR INHIBITORS, COMPOSITIONS, AND METHODS RELATED THERETO | DHFR, DHODH, FPGS | MGAM 2855/4885GAA 391/4885SI 1167/4885 |
| US-10774073-B2 | Compositions and methods for treating infections | DHFR, DHODH, QDPR | MGAM 1905/4885GAA 641/4885SI 1423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.